Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $15.03 Analyst target: $34.60 Upside: 130.21%
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.